In the SURMOUNT-2 trial, individuals with obesity and type 2 diabetes had a more than 15% reduction in weight and an almost 6% reduction in A1C while taking the dual incretin inhibitor tirzepatide. Researchers, including W. Timothy Garvey, MD, MACE, the trial’s principal investigator, discussed how a weight-focused approach can help treat obesity and type 2 diabetes.
Get email updates from ADAMeetingNews.org
Subscribe to get regular news updates about the Scientific Sessions.
You can also subscribe to receive other email communications from the American Diabetes Association.